Xinhanglu Medical Technology (Guangzhou)
Cardiac technology company advancing electrophysiology with next-gen mapping and integrated PFA platform for heart rhythm patients.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
* | CNY600m | Series B | |
| Total Funding | 000k | ||
Related Content
EnChannel Medical, founded in 2020, is a cardiac technology company headquartered in Guangzhou, China, with a subsidiary in Irvine, CA. The company specializes in developing advanced electrophysiology solutions, focusing on a next-generation mapping system and an integrated Pulsed Field Ablation (PFA) platform. EnChannel Medical aims to enhance the quality of life for patients with complex cardiac arrhythmias by providing intuitive, safer, and more effective personalized solutions. The company serves the global healthcare market, targeting medical professionals and institutions dealing with heart rhythm disorders. EnChannel Medical operates on a business model that combines cutting-edge technology with clinical expertise to deliver high-value medical devices. Revenue is generated through the sale of these specialized cardiac solutions. The leadership team, including CEO and Co-Founder Jun Feng, brings over 30 years of experience in clinical medical work, medical technology marketing, and high-tech consumable sales.
Keywords: cardiac, electrophysiology, mapping system, PFA platform, arrhythmias, personalized solutions, healthcare, medical devices, global market, clinical expertise.